The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Bioreceptor 
Aims: The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments and complications that people with thoracic tumor may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic tests and treatment for thoracic cancer.
Diagnosis: Thoracic Cancer
Principal Investigator: John Howington, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Ujala Bokary at 847.570.1783
Open to Enrollment: Yes

E2511: A Phase I and Randomized Phase II Double Blind Clinical Trial of Displatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer
Aims: The purpose of this study is two parts. In the first part of the study (phase I) we wanted to first ascertain that it is safe to allow patients to take an additional investigational pill (veliparib) along with the standard chemotherapy (cisplatin and etoposide) for the treatment of their lung cancer. Cisplatin and etoposide were chosen for this trial because the benefits and risks are well known, and because together they are one of the most effective therapies against small cell lung cancer or large cell neuroendocrine NSCC. In the second part of this study (phase II) we want to compare the effects, good and/or bad, of veliparib or a placebo (inactive pill) when combined with the standard commonly-used drugs (cisplatin and etoposide) on you and your type of lung cancer to find out which is better. If you participate in the second part of this study, you will get either veliparib or the placebo pill. You will not get both. However, you will get the standard chemotherapy drugs irrespective of which type of pill you are getting. You are being asked to take part in the phase II portion of the study.
Diagnosis: Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH13-193
Sponsor: Eastern Cooperative Oncology Group (ECOG)
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

ABI-007-NSCL-005: Safety and efficacy of nab ® -paclitaxel (Abraxane ®) in combination with carboplatin with carboplatin as first line treatment in elderly subjects with advanced non-small cell lung cancer (NSCLC): A Phase IV, randomized, open-label, multicenter study
Aims: This study will compare two schedules of this combination in patietns who are at least 70 years old. The purpose of this study is to find out which nab-paclitaxel/caboplatin schedule is better tolerated and to compare efficacy between the two schedules.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-256
Sponsor: Celgene Corporation
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Aims: The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample. This study related "research test" will be done in a special lab. The system of assigning a treatment sub-study based on genetic testing of cancer is investigational; in squamous cell lung cancer patients, we don’t know whether testing can identify patients who will or will not benefit from treatment. The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it is unsafe for you to receive the investigational treatment. You may also choose to not participate in the treatment portion of the study. Before you decide to get treatment on the study, you will be given information about the study treatment and you will be asked if you wish to continue on this research study.
Diagnosis: Squamous Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-415
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

M11-089: Randomized, Double-Blind, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)
Aims: This study is being done to research the effects of an investigational drug called veliparib in subjects with squamous NSCLC.Veliparib (also sometimes known as ABT-888) is a PARP inhibitor (blocker) that is not approved for use in advanced or metastatic NSCLC by the United States Food and Drug Administration (FDA) or by regulatory authorities in other countries outside of the US. PARP is a naturally occurring protein made by your body that may help cancer cells overcome injury or damage caused by radiation and certain types of anti-cancer drugs, making these treatments less effective. Veliparib inhibits (blocks) the activity of PARP. This blocking activity may prevent the cancer cell from repairing itself and resume growing.
Diagnosis: Squamous Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH14-287
Sponsor: AbbVie Inc.
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

CALGB 140503: A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer
Aims: The purpose of this study is to investigate two types of surgery for patients with small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancers. The study will evaluate the effectiveness of the surgery in keeping the tumor from recurring as well as the effect of the different surgeries on lung function. The study will also examine the use of CT and PET scans in detecting cancer.
The Study duration: Surgery is scheduled and the patient will be in the hospital postoperatively as determined by the physician.
Follow-up: After surgery the patient will be followed for a minimum of 5 years: post operatively as determined by the surgeon, then every 6 months for 2 years, then annually.
Diagnosis: Non-Small Cell Lung Cancer ≤ 2 cm located in the periphery of the lung.
Principal Investigator: John Howington, MD
IRB Approval Number: EH12-430
Sponsor: Cancer and Leukemia Group B (CALGB)
Contact: For more information, interested participants may contact the Surgical Research Office at 847.570.1783 or ubokhary@northshore.org
Open to Enrollment: Yes

E4512: Testing the Addition of Deug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Aims: The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI(R)), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. In addition of crizotinib may help prevent your cancer from returning, but it could also casue side effects. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: John Howington, MD
IRB Approval Number: EH15-121
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Aims: The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specificially target tumors that have these genetic changes.
Diagnosis: Resectable or Resected Lung Cancer
Principal Investigator: John Howington, MD
IRB Approval Number: EH15-122
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A Multicenter, Randomized Trial of Esophagetcomy and Cervical Esophagogastrostomy With (Two-stage) or Without (One-stage) Prior Ischemic Gastric Conditioning by Laparoscopic Ligation of Left Gastric and Short Gastric Arteries
Aims: The study aims to determine if ischemic gastric preconditioning by cutting part of the blood supply to the stomach several days before the esophagectomy procedure minimizes side effects.  It will also examine if there is a difference in the quality of life (QOL) of patients in two arms of the study as assessed by validated questionnaires.
Diagnosis:  Surgical candidates for esophageal cancer
Principal Investigator: 
Ki Wan Kim, MD
IRB Approval Number: 
EH15-175
Sponsor:
  NorthShore University HealthSystem
Contact:  Interested patients may contact Jen Jaffe, MPH, CCRP at 847-570-2803 jjaffe@northshore.org or Ujala Bokhary, MBBS, CCRP at 847-570-1783 ubokhary@northshore.org  

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Aims: The purpose of this research study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatement against patients who are treated with the standard treatment plus erlotinib (and investigational drug).
Diagnosis: Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: John Howington, MD 
IRB Approval Number: EH15-123
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A221303: Randomized Study of Early Palliative Care Integreated with Standard Oncology Care Versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Aims: The purpose of this research study is to see whether patients who receive care from palliative care doctors and nurses at an earlier time in their disease, along with their regular cancer care, will experience less emotional and physical issues from their cancer.
Diagnosis: Incurable Lung Cancer
Principal Investigator: Jennifer Obel, MD
IRB Approval Number: EH15-215
Sponsor: Alliance
Contact: Interested patients should contact research nurse Susan Greve, RN at 847.570.1183
Open to Enrollment: Yes

AbbVie M14-359: A Randomized, Open-Label, Multicenter, Phase 2 Trial Comparing Velparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who are Current or Former Smokers
Aims: The main purpose of this study is to determine if subjects with advanced or metastic non-squamous NSCLC repond better with valiparib in combination with carboplatin and paclitaxwl compared to Investigator's choice of standard chemotheraoy in subjects with metastatic or advanced non-small cell lung cancer (NSCLC).
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH14-401
Sponsor: AbbVie
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

 

× Alternate Text